|Application:||Gene expression microarray analysis|
|Number of samples:||189|
|Release date:||Oct 1 2015|
|Last update date:||Aug 9 2018|
|Diseases:||Charcot-Marie-Tooth Disease, Diabetes Mellitus, Type 1, Meningioma|
|Dataset link||Canakinumab treatment for recent-onset type 1 diabeties mellitus: a multicenter randomized, placebo-controlled trial|
Transcriptional signatures were induced in healthy cryopreserved human donor peripheral blood mononuclear cells (UPN727) through exposure to 40% subject serum in a 9 hour co-culture. Sixty-Three randomly selected subjects (43 Canakinumab treatment; 20 placebo treatment) were analysed blindedly to treatment assignment. The statistical significance of differential gene expression was determined through ANalysis Of VAriation (ANOVA) and false discovery rates (FDR) using Partek Genomics Suite 6.5.